At a glance
ClinicalIndex Comparison RecordN/AUnknown· 18 enrolled
Drug / intervention
RiaGevdietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Comparator-controlled, Cross-over Study to Investigate the Safety and Efficacy of RiaGev™ in Healthy Adults
In Brief
A clinical study evaluating RiaGev for Metabolic Syndrome and Premature Aging. Targeting 18 participants across 1 site.
Detailed Summary
This current randomized, double-blind, comparator-controlled, cross over study investigates the efficacy and safety of RiaGev™ via evaluation of NAD+, ATP, glucose, insulin, glutathione, and cortisol levels in healthy adults of ages 36-65.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetabolic Syndrome, Premature Aging
CountriesUnited States
CollaboratorsKGK Science Inc., University of Washington
Timeline
N/AUnknownOverdue
2020202120222023202420252026
Enrollment StartOct 2019
First PostedJul 2020
Primary CompletionJul 2020
Study CompletionNov 2020
TodayJul 2026
First PostedJul 23, 2020
Enrollment StartOct 25, 2019
Primary CompletionJul 30, 2020
Study CompletionNov 30, 2020
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 5.9 years ago
Interventions
RiaGevdietary
Dietary supplementation